Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

2NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED BALANCE SHEETS(In thousands)(Unaudited)ASSETSSeptember 30, 2010December 31, 2009 (1)Current assets:Cash and cash equivalents

$
2,906$
49,597Short-term investments

290,396346,614Accounts receivable

5,5534,801Inventory

11,4606,471Other current assets

6,1196,183Total current assets

$
326,434$
413,666Property and equipment, net

97,68678,263Goodwill

76,50176,501Other assets

1,8557,088Total  assets

$
502,476$
575,518LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$
4,403$
3,066Accrued compensation

10,55210,052Accrued expenses

12,3524,354Accrued clinical trial expenses

12,75914,167Deferred revenue, current portion

40,232115,563Interest payable

581,805Other current liabilities

4,4764,009Total current liabilities

$
84,832$
53,016Convertible subordinated notes

214,955214,955Capital lease obligations

17,40218,800Deferred revenue

69,03376,809Deferred gain

4,3715,027Other long-term liabilities

4,9364,544Total liabilities

$
395,529$
473,151Commitments and contingenciesStockholders' equity:Preferred stock

$
-$
-Common stock

99Capital in excess of par value

1,347,8001,327,942Accumulated other comprehensive income

1,1051,025Accumulated deficit

(1,241,967)(1,226,609)Total stockholders' equity

$
,947$
2,367Total liabilities and stockholders' equity

$
502,476$
575,518(1) The consolidated balance sheet at December 31, 2009 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. NEKTAR THERAPEUTICSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except per share
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... , July 22, 2014  Vernalis plc (LSE: ... of proof-of-concept (POC) for CCP-08, the third programme ... cough cold collaboration. Under this collaboration, POC requires ... successful human pilot comparative study against an immediate ... POC, Vernalis will make a milestone payment to ...
(Date:7/21/2014)... , July 21, 2014 McCord ... patent (U.S. Patent No. 8,796,315). This patent describes ... wound healing.  According to the inventor, Dr. McCord, ... who require wound healing, a composition of an ... derived from umbilical cord blood, such that the ...
(Date:7/21/2014)... , July 21, 2014  EHE International, the recognized ... a nationwide physician network, today announced that Dignity Health ... NV has been named an EHE-certified preventive ... Las Vegas region now have greater ... maintain their health. "EHE is proud ...
Breaking Medicine Technology:Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3US Patent Office Grants McCord Research Endothelial Cell Treatment Patent 2EHE International Certifies Dignity Health Medical Group Nevada, LLC as Its Newest Partner 2
... LOS ANGELES & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 17, ... focused on,the discovery and development of novel, ... of AV-412, a novel,next generation oral tyrosine ... mutant and drug-resistant lung cancer tumor,models. The ...
... Decreased Tumor Blood Vessel,Density and Serum PSA ... and TUSTIN, Calif., April 17, 2007,/PRNewswire-FirstCall/ -- ... company developing targeted,monoclonal antibodies for the treatment ... today announced that preclinical data,presented at the ...
Cached Medicine Technology:AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 2AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 3AVEO Presents Preclinical Efficacy Data on AV-412, a Novel Oral,Tyrosine Kinase Inhibitor of EGFR/HER2 for EGFR Mutant and,Drug-Resistant Lung Cancer 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 2Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 3Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 4Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus,Docetaxel Reduces Growth of Both Hormone-Dependent and,Hormone-Independent Prostate Cancer by Up to 94 Percent in,Preclinical Studies 5
(Date:7/22/2014)... Cloud+MD Office 2.0 is a ... medical software and services, designed by experienced healthcare ... “Actionable Information” to help Independent Physician Practices, New ... Services optimize a wide range of business processes ... Noticeable Cost Reductions and Better Patient Care. ...
(Date:7/22/2014)... An Ideal Location , Narconon Arrowhead, ... naturally tranquil and very beautiful Arrowhead State Park, overlooking ... for both a rehabilitative setting, as well as a ... of fireworks. Launched over the waters of the ... in the lake, or from the nearby campgrounds and ...
(Date:7/22/2014)... 22, 2014 MonaVie announces today that ... Advisory Board (SAB). The addition of Macdonald will help ... current product development plans and necessary substantiation for research ... Macdonald has been with the company as its nutrition ... helping formulate MonaVie’s RVL and CORE ...
(Date:7/22/2014)... 22, 2014 Joining Conquer Paralysis Now as ... the next decade is Paralympic silver medalist and quadriplegic Jennifer ... became a quadriplegic from a spinal cord injury in 1998. ... a cure for paralysis. , “People define cure differently,” French ... something else. We have the image in our minds of ...
(Date:7/22/2014)... Beach, Florida (PRWEB) July 22, 2014 ... alcohol treatment center located in Pompano Beach, ... approval from the Joint Commission, an independent not-for-profit ... United States. Accreditation signifies that the quality programs ... Joint Commission standards for safety and performance. Ocean ...
Breaking Medicine News(10 mins):Health News:Cloud-MD Software will soon Receive MU2 Certification 2Health News:Narconon Arrowhead Holds Annual Firework Event 2Health News:Narconon Arrowhead Holds Annual Firework Event 3Health News:MonaVie Adds Nutritionist Mark Macdonald to Its Scientific Advisory Board 2Health News:MonaVie Adds Nutritionist Mark Macdonald to Its Scientific Advisory Board 3Health News:Paralympian Jen French Announced as Conquer Paralysis Now’s First Champion 2Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 2Health News:Florida Drug and Alcohol Addiction Treatment Center Receives Joint Commission Seal of Approval 3
... an effective vaccine against recurrent kidney cancers.// Kidney cancer ... causes about 12,000 deaths in the United States every ... 50s and 60s. Standard treatment involves removal of all ... however, kidney cancer does not respond well to subsequent ...
... shown that a chemotherapy regimen combining vinorelbine (Navelbine) and ... the treatment of hormone-refractory prostate cancer . Specialists say ... in their disease. , However researchers added ... regimen is planned. From a group of 66 patients ...
... Breast cancer survivors can now get up and ... // older women, reported higher body esteem and ... a new study. ,Researchers compared 40 ... sedentary women, all early-stage breast cancer survivors. Regular ...
... has shown that there may be a link of type ... blood has high amounts of iron.// ,In this ... with no history of diabetes, cardiovascular disease or cancer. 700 ... iron concentration of 109 nanograms/milliliter manifested with diabetes whereas ...
... placing a soft plastic tube or catheter into the ... Patients must undergo training for two weeks and ... from the comfort of their home. Hemodialysis patients can ... attached to a blood-cleaning machine at a dialysis center. ...
... replacement therapy among breast cancer survivors has been // stopped ... or new cancers. ,Swedish researchers embarked on the study ... therefore subject to the same menopausal symptoms as other women. ... five years. After the initial 345 women in the study ...
Cached Medicine News:Health News:A Combination Of Drugs Effective In The Treatment Of Hormone-Refractory Prostate Cancer 2
Open wire loops decrease the chance of interfering with instruments, Designed to retract the eyelid during ophthalmic microsurgery or minor office procedures...
For rotating nucleus during phacoemulsification, Also useful for dislocating the nucleus into the anterior chamber during extracapsular cataract extraction, 45, Blunt, Forked, 9.0mm from end...
... drape has two perforations which ... to various single or bilateral ... Refractive drape has two perforations ... adapts to various single or ...
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Medicine Products: